Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ADMA Biologics (ADMA)

ADMA Biologics Q3 revenue rises 5% to $141.1 million; raises adjusted earnings outlook

Positive Impact 4 of 5 earnings

ADMA Biologics reported third quarter 2026 total revenue of $141.1 million, up 5% from a year earlier, and GAAP net income of $49.9 million, up 37%. The company reiterated its FY2026 revenue outlook of at least $530 million and raised its minimum expectations for Adjusted Net Income and Adjusted EBITDA. BIVIGAM revenue fell from the prior-year quarter, a trend the company says showed signs of stabilizing.

Key points

  • Q3 2026 ASCENIV revenue was $124.7 million, up 31% year-over-year; BIVIGAM revenue was $15.4 million, down from $23.8 million a year earlier.
  • GAAP net income was $49.9 million, or $0.22 basic EPS, compared with $36.4 million and $0.15 in the prior-year quarter.
  • FY2026 outlook: total revenue at least $530 million (reiterated), Adjusted Net Income at least $180 million, and Adjusted EBITDA at least $275 million (both raised).
  • The company repurchased 2.7 million shares in the third quarter and is on track for a $200 million or more 2026 buyback target.

The filing

CompanyADMA Biologics (ADMA)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:10 PM ET
Accession number0001140361-26-041959

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.